Meeting
2014 Gastrointestinal Cancers Symposium
Phase I and pharmacokinetics/pharmacodynamics (PK/PD) study of MEK inhibitor, RO4987655, in Japanese patients with advanced solid tumors.
Authors
Yasuhide Yamada
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Yasuhide Yamada , Hiroshi Nokihara , Noboru Yamamoto , Yutaka Fujiwara , Yosuke Tamura , Hiroshi Wakui , Kazunori Honda , Shinji Nakamichi , Hajime Asahina , Yuko Tanabe , Satoru Kitazono , Hidenori Mizugaki , Naoya Yamazaki , Shigenobu Suzuki , Junichi Sasaki , Mieko Matsuoka , Tomohide Tamura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
JapicCTI-111490
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 116)
DOI
10.1200/jco.2014.32.3_suppl.116
Abstract #
116
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
First Author: Rebecca Suk Heist
Poster
2020 ASCO Virtual Scientific Program
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2015 ASCO Annual Meeting
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
First Author: Kristen Renee Spencer